Purdue Research v. Sanofi-Synthelabo

Court of Appeals for the Seventh Circuit·Decided August 4, 2003·No. 02-2655·Published

Opinion

In the

United States Court of Appeals For the Seventh Circuit

No. 02-2655 PURDUE RESEARCH FOUNDATION, Plaintiff-Appellant,

v.

SANOFI-SYNTHELABO, S.A., SANOFI-SYNTHELABO, INCORPORATED, and STWB, INCORPORATED, Defendants-Appellees.

Appeal from the United States District Court for the Northern District of Indiana, Hammond Division.

No. 02 C 4—Allen Sharp, Judge.

ARGUED DECEMBER 9, 2002—DECIDED AUGUST 4, 2003

Before BAUER, RIPPLE and KANNE, Circuit Judges. RIPPLE, Circuit Judge. Purdue Research Foundation (“PRF”), an Indiana corporation with its principal place of business in West Lafayette, Indiana, filed this action for breach of contract in the Superior Court for Tippecanoe County, Indiana, against Sanofi-Synthelabo, S.A. (“SSBO France”), a French corporation with its principal place of 2 No. 02-2655

1

business in Paris, France. PRF alleged that it was entitled to payments relating to the development of an antiviral drug, known as pleconaril, under a Cooperative Research Agreement that SSBO France had acquired from Sterling Winthrop, Inc. through an asset purchase agreement. Invoking the diversity jurisdiction of the district court, see 28 U.S.C. § 1332, SSBO France removed the case to the United

2

States District Court for the Northern District of Indiana.

1 PRF also named Sanofi-Synthelabo, Inc. (“SSBO U.S.”), a Delaware corporation with its principal place of business in New York, and STWB, Inc. (“STWB”), a now-defunct Delaware corporation, as defendants. The district court, however, dismissed these defendants for misjoinder, and PRF does not appeal that determination. 2 In its Notice of Removal, SSBO France asserted that the district court had subject matter jurisdiction over this case pursuant to both 28 U.S.C. § 1332 (diversity of citizenship) and 28 U.S.C. § 1338 (patent construction). The United States Court of Appeals for the Federal Circuit has exclusive jurisdiction over appeals in which the jurisdiction of the district court is based, in whole or in part, on the construction of a patent under 28 U.S.C. § 1338. See 28 U.S.C. § 1295(a)(1); see also Aura Lamp & Lighting, Inc. v. Int’l Trading Corp., 325 F.3d 903, 906-07 (7th Cir. 2003). Although the district court’s docket therefore reflects that its jurisdiction is based on the existence of a federal question, we note that the proper jurisdictional basis is diversity of citizenship. There is complete diversity of citizenship between the plaintiff and the defendants, and the matter in controversy exceeds the value of $75,000. See 28 U.S.C. § 1332. Patent law jurisdiction extends only to those cases in which “ ‘federal patent law creates the cause of action’” or “ ‘the plaintiff’s right to relief necessarily depends on resolution of a substantial question of federal patent law, in that patent law is a necessary element of one of the well-pleaded claims.’” U.S. Valves, Inc. v. Dray, 190 F.3d 811, 813 (7th Cir. 1999)

(continued...)

No. 02-2655 3

The district court dismissed PRF’s complaint against SSBO France for want of personal jurisdiction. For the reasons set forth in the following opinion, we affirm the judgment of the district court.

I

BACKGROUND

A. Facts PRF is the contracting authority for all sponsored research undertaken at Purdue University. SSBO France is a French corporation in the business of developing, manufacturing and selling pharmaceuticals.

On December 1, 1987, PRF entered into a five-year Cooperative Research Agreement (“Agreement”) with Sterling Drug, Inc. (“Sterling Drug”) for the purpose of developing

3

certain antiviral drugs. The Agreement acknowledged that Dr. Michael Rossmann and other Purdue scientists had been cooperating with Sterling scientists since January 1,

2 (...continued) (quoting Christianson v. Colt Indus. Operating Corp., 486 U.S. 800, 809 (1988)). Because neither situation is present in this case, we have jurisdiction over this appeal. 3 We focus on the first agreement but note that PRF actually entered into three separate Cooperative Research Agreements with Sterling Drug between December 1, 1987, and December 1, 1992. However, PRF has made no effort to differentiate the later agreements from the 1987 agreement. More importantly, the parties express no disagreement over the fact that research under these agreements is completed, and this litigation solely concerns PRF’s claim that it is owed compensation because its research led to a successful product.

4 No. 02-2655

1986, that their research had led to an increased understanding of the interaction between certain viruses and antiviral agents, and that the parties desired to continue their relationship in order to further develop antiviral agents of interest to Sterling Drug. The Agreement obligated Sterling Drug to compensate PRF for product achievements related

4

to the sponsored research.

Under the Agreement, PRF and Sterling Drug agreed to share the cost of their collaborative research efforts, both contributing $50,000 for each of the five years. Sterling Drug further agreed to furnish Dr. Rossmann and his associates with adequate supplies of picornavirus and other viruses for research to be performed at Purdue University. In addition, both PRF and Sterling Drug agreed to provide the other with an annual written report summarizing the work carried out under the Agreement by Purdue scientists

4 The Agreement recognized that the collaborative research could lead to four types of product achievements: (1) joint inventions , (2) inventions made solely by Sterling Drug personnel, (3) inventions made solely by Purdue University personnel, and (4) inventions made jointly with third parties. In regard to the second category, which is at issue in this litigation, the Agreement provided that any invention, which “is conceived or first actually reduced to practice in the course of work under this Agreement,” and which, “under United States law, is an invention solely of Sterling personnel, shall be owned by Sterling alone.” R.1, “Cooperative Research Agreement” at ¶ 7.2(b). With respect to any such invention, the parties agreed “to negotiate in good faith to determine a percentage that Sterling will pay PRF based on net sales of any product, the manufacture, use or sale of which would infringe a claim of an issued, unexpired and enforceable patent or a published patent application covering one or more aspects of the invention if the patent or application were not owned by Sterling.” Id. at ¶ 9.1.

No. 02-2655 5

at the University and by Sterling scientists at Sterling’s facilities. Sterling Drug also agreed to indemnify PRF for any liability arising from the manufacture, use, distribution or sale of products by Sterling Drug, its affiliates or licensees . The Agreement provided for the application of Indiana law, but it did not contain a choice of forum clause or a stipulation as to personal jurisdiction in Indiana. Also, the Agreement permitted Sterling Drug to assign the contract to any entity that succeeded to substantially all of Sterling Drug’s ethical pharmaceutical business.

By its terms, the research component of the Agreement

5

expired on December 1, 1992. During the period of the Agreement, PRF and Sterling Drug worked on and evaluated various antiviral chemical compounds. According to PRF, this research, which was conducted primarily in West Lafayette, Indiana, contributed to the development of pleconaril, an antiviral drug intended to treat the common cold. On September 20, 1994, Sterling Winthrop, Inc. (“Sterling Winthrop”), the successor to Sterling Drug, was granted a patent for the chemical compound known as

6

pleconaril.

In 1994, the intellectual property relating to Sterling Winthrop’s ethical pharmaceutical business was purchased by Sanofi, S.A. (“Sanofi France”), a French corporation, and Sanofi Winthrop, Inc. (“Sanofi Winthrop”), a Delaware corporation and subsidiary of Sanofi France. Relevant to this

Free access — add to your briefcase to read the full text and ask questions with AI

Purdue Research v. Sanofi-Synthelabo, (7th Cir. 2003).

Purdue Research v. Sanofi-Synthelabo (Purdue Research v. Sanofi-Synthelabo) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Dickson Marine Inc. v. Panalpina, Inc.
179 F.3d 331 (Fifth Circuit, 1999)
Alpine View Co Ltd v. Atlas Copco AB
205 F.3d 208 (Fifth Circuit, 2000)
Patin v. Thoroughbred Power Boats Inc.
294 F.3d 640 (Fifth Circuit, 2002)
Consolidated Development Corp. v. Sherritt, Inc.
216 F.3d 1286 (Eleventh Circuit, 2000)
Meier Ex Rel. Meier v. Sun International Hotels, Ltd.
288 F.3d 1264 (Eleventh Circuit, 2002)
International Shoe Co. v. Washington
326 U.S. 310 (Supreme Court, 1945)
Hanson v. Denckla
357 U.S. 235 (Supreme Court, 1958)
World-Wide Volkswagen Corp. v. Woodson
444 U.S. 286 (Supreme Court, 1980)
Keeton v. Hustler Magazine, Inc.
465 U.S. 770 (Supreme Court, 1984)
Calder v. Jones
465 U.S. 783 (Supreme Court, 1984)
Helicopteros Nacionales De Colombia, S. A. v. Hall
466 U.S. 408 (Supreme Court, 1984)
Burger King Corp. v. Rudzewicz
471 U.S. 462 (Supreme Court, 1985)
Christianson v. Colt Industries Operating Corp.
486 U.S. 800 (Supreme Court, 1988)
United States v. Swiss American Bank, Ltd.
274 F.3d 610 (First Circuit, 2001)
Logan Productions, Inc. v. Optibase, Inc.
103 F.3d 49 (Seventh Circuit, 1996)